DiaMedica is committed to developing novel therapeutics for patients with serious and life-threatening diseases. DiaMedica’s lead candidate, DM199 (recombinant human KLK1) is being evaluated in phase 2 clinical trials for the treatment of several chronic and acute diseases.
Chronic Kidney Disease (CKD)
CKD is a chronic disease which may be caused by a wide variety of issues. There is currently no approved treatment for CKD. Available treatments are limited to the management of symptoms and therefore CKD represents a significant unmet medical need. Initially, DiaMedica Is conducting a clinical study in CKD caused by IgA Nephropathy (IgAN) and hypertensive non-diabetic African Americans with or without the APOL1 gene mutation.
Acute Ischemic Stroke (AIS)
AIS is one of the leading causes of adult disability. Currently only one drug is approved for the treatment of AIS, but It must be administered within approximately 4 hours of stroke onset. Given the short treatment window, approximately 90% of AIS victims receive no direct treatment for their stroke.